文献速递肺外科

丁酸梭菌预防性用药减少肺切除术后感染:倾向评分加权分析

Probiotic Prophylaxis With Clostridium butyricum for Postoperative Infections Following Lung Resection: A Propensity Score-Weighted Analysis.
PubMed 文献 · Ann Thorac Surg · 2025-10-09

该单中心回顾性队列研究纳入529例胸腔镜解剖性肺切除的原发性肺癌患者,比较围手术期丁酸梭菌MIYARI 588(CBM588)组与对照组。经逆概率加权调整后,益生菌组器官/腔隙手术部位感染(OSS)和所有术后感染风险显著降低,但总体并发症、住院时间、30/90天死亡率、再手术及再入院率无显著差异。

要点

  • 围手术期CBM588与胸腔镜解剖性肺切除后OSS风险显著降低相关(OR 0.08)。
  • CBM588组所有术后感染风险亦显著低于对照组(OR 0.26)。
  • 总体并发症、住院时间、死亡率、再手术及再入院率未见显著差异。

核心结论

  • 围手术期CBM588可能降低胸腔镜解剖性肺切除术后OSS及所有术后感染风险,提示潜在预防获益。

主要发现

  • IPW调整后,益生菌组OSS发生率显著低于对照组(OR 0.08;95% CI 0.01-0.64;P = .017)。
  • 未调整的所有术后感染发生率益生菌组为4.2%(3/71),对照组为9.8%(45/458);IPW调整后益生菌与所有术后感染风险显著降低相关(OR 0.26;95% CI 0.07-0.95;P = .042)。
  • 总体并发症率、IPW调整后住院时间、30天或90天死亡率、再手术率及再入院率均无显著差异。
  • 未调整亚组分析显示非复杂患者住院时间略有缩短。

临床怎么用

  • 对于拟行胸腔镜解剖性肺切除的原发性肺癌患者,可考虑围手术期使用CBM588以降低术后感染风险,但需结合患者个体情况并等待进一步验证。

局限性

  • 回顾性单中心设计,益生菌组样本量较小(n=71),且两组手术时间跨度不同,可能存在未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the efficacy and safety of perioperative Clostridium butyricum MIYARI 588 (CBM588) for preventing postoperative infections following thoracoscopic anatomic lung resection for primary lung cancer, with the hypothesis of a reduction in organ/space surgical site infection (OSS). Postoperative infections, particularly OSS, are a significant concern after lung resection. Although probiotics have shown promise in reducing infections in gastrointestinal surgery, their role in thoracic surgery is unclear. METHODS: This retrospective, single-center cohort study analyzed 529 patients undergoing thoracoscopic anatomic lung resection for primary lung cancer. The study compared a control group (n = 458, operated on between January 2014 and December 2021) with a probiotic group (n = 71, operated on between April 2020 and December 2021) that received perioperative CBM588 after a change in institutional practice. Inverse probability weighting (IPW) adjusted for baseline and surgical confounders. RESULTS: After IPW adjustment, the probiotic group demonstrated a significantly lower incidence of OSS (odds ratio, 0.08; 95% CI, 0.01-0.64; P = .017). The unadjusted incidence of all postoperative infections was 4.2% (3/71) in the probiotic group vs 9.8% (45/458) in the control group; after IPW adjustment, probiotics were associated with a significantly lower risk of all postoperative infections (odds ratio, 0.26; 95% CI, 0.07-0.95; P = .042). No significant differences were found in overall complication rates, IPW-adjusted hospital stay, 30- or 90-day mortality, reoperation, or readmission rates. An unadjusted subgroup analysis revealed a minor reduction in hospital stay for noncomplicated patients. CONCLUSIONS: Perioperative CBM588 may reduce OSS and all postoperative infections following thoracoscopic anatomic lung resection, suggesting a potential prophylactic benefit.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Murakami J, Tanaka T, Shimokawa M, et al. Probiotic Prophylaxis With Clostridium butyricum for Postoperative Infections Following Lung Resection: A Propensity Score-Weighted Analysis. Ann Thorac Surg. 2025. PMID: 41072599. doi:10.1016/j.athoracsur.2025.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。